Neostigmine


Generic Medicine Info
Contraindications
Peritonitis, mechanical GI or urinary obstruction.
Special Precautions
Patient w/ bronchial asthma, CV disorders (e.g. bradycardia, recent MI, hypotension), peptic ulcer disease, vagotonia, epilepsy, parkinsonism, hyperthyroidism. Patient who underwent recent intestinal or bladder surgery. Renal impairment. Childn. Pregnancy and lactation. Monitoring Parameters Monitor ECG, BP and heart rate esp w/ IV use.
Adverse Reactions
Nausea and vomiting, increased salivation, diarrhoea and abdominal cramps; hypersensitivity reactions (e.g. anaphylaxis, urticaria, angioedema); neuromuscular dysfunction in high doses of IV preparation.
Potentially Fatal: Resp failure, due to a combination of muscarinic, nicotinic and central effects or cardiac arrest.
Drug Interactions
May potentiate neuromuscular blockade w/ depolarising muscle relaxants (e.g. suxamethonium) resulting to prolonged apnoea. Drugs w/ neuromuscular blocking activity (e.g. aminoglycosides, clindamycin, colistin, cyclopropane, halogenated inhalational anaesth) may antagonise the effects of neostigmine. Reduced effects w/ quinine, chloroquine, hydroxychloroquine, quinidine, procainamide, propafenone, lithium. Prolonged bradycardia w/ β-blockers.
ATC Classification
N07AA01 - neostigmine ; Belongs to the class of anticholinesterase. Used as parasympathomimetics.
S01EB06 - neostigmine ; Belongs to the class of parasympathomimetics. Used in the treatment of glaucoma and miosis.
Disclaimer: This information is independently developed by CIMS based on neostigmine from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in